Global Human Microbiome Market Growth (Status and Outlook) 2025-2031

Global Human Microbiome Market Growth (Status and Outlook) 2025-2031

The global Human Microbiome market size is predicted to grow from US$ 556 million in 2025 to US$ 1880 million in 2031; it is expected to grow at a CAGR of 22.5% from 2025 to 2031.

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that"s 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.

LPI (LP Information)' newest research report, the “Human Microbiome Industry Forecast” looks at past sales and reviews total world Human Microbiome sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Microbiome sales for 2025 through 2031. With Human Microbiome sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Microbiome industry.

This Insight Report provides a comprehensive analysis of the global Human Microbiome landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Human Microbiome portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Microbiome market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Microbiome and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Microbiome.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Microbiome market by product type, application, key players and key regions and countries.

Segmentation by Type:
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others

Segmentation by Application:
Treatment
Diagnosis

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC

Please note: The report will take approximately 2 business days to prepare and deliver.